Build status - In Progress

UPCC 28921: A Phase I/IIa Open-label Multi-centre Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART4215 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumours

Enrolling By Invitation
99 years or below
All
1 Location

Brief description of study

This study has a mono therapy arm and a combination therapy arm. The main purpose of the mono therapy arm is to test the safety and tolerability of ART4215 in humans. The main purpose of the combination therapy arm is to test ART4215 compared to and in combination with talazoparib.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 14 Jun 2023. Study ID: 850528
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research